Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase

Oncogene

Volumn 25, Issue 45, 2006, Pages 6092-6100

  Keating, A K ^a   Salzberg, D B ^a   Sather, S ^a   Liang, X ^b   Nickoloff, S ^a   Anwar, A ^a   DeRyckere, D ^a   Hill, K ^a   Joung, D ^a   Sawczyn, K K ^a   Park, J ^a   Curran Everett, D ^b,c   McGavran, L ^b   Meltesen, L ^b   Gore, L ^a   Johnson, G L ^d   Graham, D K ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Leukemia; Lymphoma; MerTK; Receptor tyrosine kinase; Transgenic mouse

Indexed keywords

DEXAMETHASONE; PROTEIN MERTK; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINEAGE; GENE OVEREXPRESSION; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; LYMPHOCYTE; LYMPHOMA; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL; THROMBOCYTE AGGREGATION; THYMOCYTE; WILD TYPE;

ANIMALS; APOPTOSIS; BASE SEQUENCE; DNA PRIMERS; FLOW CYTOMETRY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, T-CELL; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 33749836690     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209633     Document Type: Article

References (49)

1. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. (1999). Oncogene 18: 5268-5277.
2. Anderson KE, Jackson SP. (2003). Int J Biochem Cell Biol 35: 1028-1033.
3. Behrens EM, Gadue P, Gong SY, Garrett S, Stein PL, Cohen PL. (2003). Eur J Immunol 33: 2160-2167.
4. Blume-Jensen P, Hunter T. (2001). Nature 411: 355-365.
5. Borgel D, Clauser S, Bornstain C, Bieche I, Bissery A, Remones V et al. (2006). Crit Care Med 34: 219-222.
6. Chen J, Carey K, Godowski PJ. (1997). Oncogene 14: 2033-2039.
7. Curran-Everett D. (2000). Am J Physiol Regul Integr Comp Physiol 279: R1-R8.
8. Dirks W, Rome D, Ringel F, Jager K, MacLeod RA, Drexler HG. (1999). Leuk Res 23: 643-651.
9. Dormady SP, Zhang XM, Basch RS. (2000). Proc Natl Acad Sci USA 97: 12260-12265.
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. (1996). Nat Med 2: 561-566.
11. Egle A, Harris AW, Bouillet P, Cory S. (2004). Proc Natl Acad Sci USA 101: 6164-6169.
12. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Genes Dev 13: 2658-2669.
13. Ek S, Hogerkorp CM, Dictor M, Ehinger M, Borrebaeck CA. (2002). Cancer Res 62: 4398-4405.
14. Evans CO, Young AN, Brown MR, Brat DJ, Parks JS, Neish AS et al. (2001). J Clin Endocrinol Metab 86: 3097-3107.
15. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC et al. (2002). Cancer Cell 1: 75-87.
16. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. (1999). Mol Cell Biol 19: 1171-1181.
17. Gilliland DG, Griffin JD. (2002). Blood 100: 1532-1542.
18. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. (1995). Oncogene 10: 2349-2359.
19. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. (1994). Cell Growth Differ 5: 647-657.
20. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK et al. (2006). Clin Cancer Res 12 (in press).
21. Graham FL, Smiley J, Russell WC, Nairn R. (1977). J Gen Virol 36: 59-74.
22. Grandage VL, Gale RE, Linch DC, Khwaja A. (2005). Leukemia 19: 586-594.
23. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. (2004). Nat Genet 36: 1084-1089.
24. Guttridge KL, Luft JC, Dawson TL, Kozlowska E, Mahajan NP, Varnum B et al. (2002). J Biol Chem 277: 24057-24066.
25. Hanahan D, Weinberg RA. (2000). Cell 100: 57-70.
26. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. (1988). J Exp Med 167: 353-371.
27. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J. (1990). Nature 344: 251-253.
28. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D et al. (1991). Blood 78: 1166-1172.
29. Jia R, Hanafusa H. (1994). J Biol Chem 269: 1839-1844.
30. Jia R, Mayer BJ, Hanafusa T, Hanafusa H. (1992). J Virol 66: 5975-5987.
31. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC et al. (1999). Proc Natl Acad Sci USA 96: 13264-13269.
32. Krause DS, Van Etten RA. (2005). N Engl J Med 353: 172-187.
33. Ling L, Kung HJ. (1995). Mol Cell Biol 15: 6582-6592.
34. Naf D, Krupke DM, Sundberg JP, Eppig JT, Bult CJ. (2002). Cancer Res 62: 1235-1240.
35. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. (1999). Blood 94: 1855-1863.
36. Pui CH, Evans WE. (1998). N Engl J Med 339: 605-615.
37. Pui CH, Relling MV, Downing JR. (2004). N Engl J Med 350: 1535-1548.
38. Reed JC. (1999). J Clin Oncol 17: 2941-2953.
39. Sattler M, Salgia R. (2004). Leuk Res 28(Suppl 1): S11-S20.
40. Savage DG, Antman KH. (2002). N Engl J Med 346: 683-693.
41. Schlessinger J. (2000). Cell 103: 211-225.
42. Schrappe M, Camitta B, Pui CH, Eden T, Gaynon P, Gustafsson G et al. (2000). Leukemia 14: 2193-2194.
43. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. (2001). Blood 97: 1211-1218.
44. Strasser A, Harris AW, Bath ML, Cory S. (1990). Nature 348: 331-333.
45. Tibes R, Trent J, Kurzrock R. (2005). Annu Rev Pharmacol Toxicol 45: 357-384.
46. Vivanco I, Sawyers CL. (2002). Nat Rev Cancer 2: 489-501.
47. Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE et al. (2004). N Engl J Med 351: 552-559.
48. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS et al. (2002). Anticancer Res 22: 1071-1078.
49. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R et al. (2002). Cancer Cell 1: 133-143.